Howard Hughes Medical Institute’s Viatris VTRS Stock Holding History

Howard Hughes Medical Institute’s Portfolio VTRS Stock Details VTRS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-376	Closed	-$4.68K	–	468
2025 Q4	$4.68K	Buy	376 +62	+20%	+$669	﹤0.01%	353
2025 Q3	$3.11K	Buy	314 +25	+9%	+$243	﹤0.01%	425
2025 Q2	$2.58K	Buy	+289	New	+$2.44K	﹤0.01%	436
2017 Q3	–	Sell	-182,350	Closed	-$7.08M	–	122
2017 Q2	$7.08M	Sell	182,350 -11,278	-6%	-$433K	1.29%	15
2017 Q1	$7.55M	Buy	193,628 +19,148	+11%	+$772K	1.39%	11
2016 Q4	$6.66M	Buy	174,480 +144,185	+476%	+$5.36M	1.52%	12
2016 Q3	$1.16M	Buy	30,295 +12,648	+72%	+$562K	0.3%	66
2016 Q2	$763K	Sell	17,647 -629	-3%	-$27.8K	0.26%	73
2016 Q1	$847K	Buy	+18,276	New	+$882K	0.19%	67
2014 Q3	–	Sell	-653	Closed	-$34K	–	196
2014 Q2	$34K	Buy	+653	New	+$32.1K	0.01%	153

Other funds holding VTRS

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

DSA

Davis Selected Advisers Tucson, Arizona $21.8B AUM 23.45% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

RCMNY

Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Howard Hughes Medical Institute's VTRS Position: Q1 2026 in Review

Howard Hughes Medical Institute sold out of Viatris (VTRS) in Q1 2026, closing a stake of 376 shares — an estimated $4.68K sold.

Howard Hughes Medical Institute first reported a position in VTRS in Q2 2014 and held it in 10 quarters. The position peaked at $7.55M in Q1 2017. 1,021 funds tracked by Wall St. Rank hold VTRS as of Q1 2026.

Howard Hughes Medical Institute reported no remaining Viatris position as of Q1 2026 after selling out during the quarter.
Howard Hughes Medical Institute sold 376 Viatris shares in Q1 2026, an estimated $4.68K.
Howard Hughes Medical Institute first reported a position in Viatris in Q2 2014 and held it in 10 quarters.
Howard Hughes Medical Institute's Viatris position peaked at $7.55M in Q1 2017.
1,021 funds tracked by Wall St. Rank held Viatris as of Q1 2026.

Based on Howard Hughes Medical Institute's 13F filing for Q1 2026, filed 15 May 2026.